Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle James R. Stelling, M.D., Emily.

Slides:

Advertisements

Similar presentations

Pregnancy rates after embryo transfer depend on the provider at embryo transfer22 Rhonda M Hearns-Stokes, M.D., Bradley T Miller, M.D., Lynette Scott,

Advertisements

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Sebiha Ozkan, M. D. , Sangita Jindal, Ph. D. , Keri Greenseid, M. D

A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome? Ronit Machtinger, M.D., Joseph.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Dramatic declines in implantation and pregnancy rates in patients who undergo repeated cycles of in vitro fertilization with blastocyst transfer after.

Craig A. H Richard, Ph. D. , Carolyn J Kubik, M. D

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Modified natural cycle in in vitro fertilization

Serum human chorionic gonadotropin levels are correlated with body mass index rather than route of administration in women undergoing in vitro fertilization–embryo.

Human chorionic gonadotropin as a predictor of outcome in assisted reproductive technology pregnancies Gillian Homan, Susan Brown, R.N., John Moran,

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval David E. Reichman,

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Oocyte cryopreservation

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review Seema Menon, M.D., John.

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Robert F. Casper, M.D. Fertility and Sterility

Association of the very early rise of human chorionic gonadotropin with adverse outcomes in singleton pregnancies after in vitro fertilization Christopher.

Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates Amy.

Early pregnancy losses in in vitro fertilization and oocyte donation

Are serum human chorionic gonadotropin clearance curves of use in monitoring methotrexate treatment in cervical pregnancy? Petra J. Hajenius, M.D., Daphne.

A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone

Human chorionic gonadotropin levels after blastocyst transfer are highly predictive of pregnancy outcome1 Theocharis C Papageorgiou, M.D., Mark P Leondires,

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Granulosa–lutein cell growth differentiation factor-9 (GDF-9) messenger RNA and protein expression in in vitro fertilization (IVF) cycles: relation to.

Elevations in PGE2 and PGF2α in human follicular fluid are associated with poor in vitro fertilization outcomes Bruce Pier, MD, Johnathan W. Edmonds,

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Pete N. Lohstroh, B. S. , James W. Overstreet, M. D. , Ph. D

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

One last chance for pregnancy: a review of 2,705 in vitro fertilization cycles initiated in women age 40 years and above Sigal Klipstein, M.D., Meredith.

Live babies born per oocyte retrieved in a subpopulation of oocyte donors with repetitive reproductive success J. Ryan Martin, M.D., Jason G. Bromer,

David E. Reichman, M. D. , Stacey A. Missmer, Sc. D. , Katharine F

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Nargund, M.D.

Bruce S Shapiro, M. D. , Kevin S Richter, Ph. D. , Dee C Harris, M. T

Regulation of assisted reproductive technologies in the United States

Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome? Luis.

Absence of corpus luteum rescue by chorionic gonadotropin in women immunized with a contraceptive vaccine Rahul Pal, Ph.D., Om Singh, Ph.D. Fertility.

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Anuja Dokras, M. D. , Ph. D. , Antonia Habana, M. D. , Juan Giraldo, M

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer Mohamed.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Interleukin-1β and interleukin-1α may affect the implantation rate of patients undergoing in vitro fertilization–embryo transfer Evdokia E Karagouni,

Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.

Use of serum inhibin A and human chorionic gonadotropin measurements to predict the outcome of in vitro fertilization pregnancies Erik Hauzman, M.D.,

M. Rafet Gazvani, Michelle Bates, Gillian Vince, Ph. D

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Day 3 morphology is a poor predictor of blastocyst quality in extended culture James Graham, M.S., Taer Han, B.S., Richard Porter, Michael Levy, M.D.,

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles David.

Increased endometrial thickness on the day of human chorionic gonadotropin injection does not adversely affect pregnancy or implantation rates following.

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient’s body mass index and the number of larger follicles

Use of recombinant human chorionic gonadotropin in ovulation induction

The follicular and endocrine environment in women with endometriosis: local and systemic cytokine production Antonio Pellicer, M.D., Carmela Albert,

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle James R. Stelling, M.D., Emily T. Chapman, B.S., David Frankfurter, M.D., Doria H. Harris, Ph.D., Selwyn P. Oskowitz, M.D., Richard H. Reindollar, M.D. Fertility and Sterility Volume 79, Issue 4, Pages 881-885 (April 2003) DOI: 10.1016/S0015-0282(02)04918-X

FIGURE 1 Serum hCG level at time of oocyte retrieval in SC and IM groups. Stelling. Subcutaneous vs. intramuscular hCG.Fertil Steril 2003. Fertility and Sterility 2003 79, 881-885DOI: (10.1016/S0015-0282(02)04918-X)

FIGURE 2 Follicular fluid hCG level at time of oocyte retrieval in SC and IM groups. Stelling. Subcutaneous vs. intramuscular hCG.Fertil Steril 2003. Fertility and Sterility 2003 79, 881-885DOI: (10.1016/S0015-0282(02)04918-X)